CN102000351A - Method for preparing chitosan-modified magnetic liposomes - Google Patents
Method for preparing chitosan-modified magnetic liposomes Download PDFInfo
- Publication number
- CN102000351A CN102000351A CN2010105714211A CN201010571421A CN102000351A CN 102000351 A CN102000351 A CN 102000351A CN 2010105714211 A CN2010105714211 A CN 2010105714211A CN 201010571421 A CN201010571421 A CN 201010571421A CN 102000351 A CN102000351 A CN 102000351A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- magnetic
- solution
- preparation
- modified magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a method for preparing chitosan-modified magnetic liposomes, which comprises the following steps: preparing magnetic nano-particles of ferroferric oxide in the presence of inert gases under the condition of severe stirring; compositing the magnetic nano-particles of ferroferric oxide with phospholipids and cosurfactant so as to prepare magnetic liposomes; and using the chitosan-modified magnetic liposomes to prepare magnetic liposomes appropriate suitable for intestinal contrast mediums. The method of the invention is simple and strong in operability, and can further satisfy the demands on production and applications. The chitosan-modified magnetic liposome prepared by using the method of the invention has good specificity to intestinal mucosal, and is helpful for improving the effective utilization rate of contrast mediums.
Description
Technical field
The present invention relates to a kind of preparation method of magnetic liposome, be specifically related to a kind of preparation method of chitosan-modified magnetic liposome, this liposome can be used as the targeted contrast agent of intestinal.
Background technology
Chitosan is a kind of positively charged natural polysaccharide, nontoxic, nonirritant, no sensitization, no mutagenic action, have excellent biological compatibility and biological degradability, amino that enriches on its strand and hydroxyl make it be easy to carry out chemical modification and are endowed multiple functional group.Chitosan as pharmaceutical carrier can control drug release, the prolong drug curative effect, reduce poisonous side effect of medicine, improve the permeability and the stability of drug of hydrophobic drug cell membrane and change route of administration, can also strengthen the target administration ability of preparation greatly.Studies show that recently chitosan has bioadhesive, can effectively increase the absorption of medicine by eye, nasal cavity and gastrointestinal tract mucous epithelium, and one of this chemical compound key property is can be by the enzymatic degradation of colon anaerobism flora secretion specificity.Therefore, chitosan has targeting to colon.
Utilize chitosan to come modified liposome, not only medicine is had protection and urgees the effect of oozing, improve the slow-releasing of medicine, can also increase the targeting of medicine, thereby reach the effect that improves bioavailability.Simultaneously, it also can reduce the toxicity of cationic-liposome, prevents that liposome from destroying at gastrointestinal tract, and to reach orally taken and colon released purpose of putting, therefore, chitosan liposome composite particles has the potential as good pharmaceutical carrier.
The fast detecting that nuclear magnetic resonance (MRI) technology can can't harm biological internal organs and soft tissue.And nuclear magnetic resonance (MRI) I technology mainly realizes by magnetic resonance contrast agent.At present, magnetic resonance contrast agent commonly used clinically is Gd-DTPA.But Gd-DTPA has the some shortcomings part,, injection back Gd-DTPA short as: circulation time can be rapidly by intercellular substance, through renal excretion, in vivo distribute do not have specificity, price is than costliness etc.Therefore, seek cheap and have the focus that specific contrast agent is a current research.Comparatively speaking, magnetic nano-particle is as magnetic resonance contrast agent, safety is better, and be easy to ligands specific is connected to the contrast agent surface, make it optionally with corresponding receptors bind, thereby reach the purpose that specificity strengthens target area ultrasonic signal or local targeted therapy, therefore be subjected to very much the welcome of clinical practice.
Summary of the invention
The object of the invention is at the deficiencies in the prior art, and a kind of preparation method of chitosan-modified magnetic liposome is provided, and technology is simple, and production cost is low, and the magnetic liposome good stability that gained is chitosan-modified can further satisfy and produce and demands of applications.
The invention provides a kind of preparation method of chitosan-modified magnetic liposome, it is characterized in that, may further comprise the steps:
A, configuration concentration are the solution of 10-20mg/ml ferric chloride, 5-10mg/ml ferrous chloride and 5-10mg/ml surfactant, with this solution under 50-80 ℃ and inert atmosphere, vigorous stirring is after 30 minutes, regulating pH value with sodium hydroxide solution is 8-11; Keep temperature, continue to stir after 30 minutes, deionized water, washing with alcohol are used in centrifugalize respectively;
B, configuration concentration are chloroform, the distilled water solution of 10-20mg/ml phospholipid and 10mg/ml cosurfactant, and the volume ratio of chloroform and water is 3: 1-1: 3; This solution rotary evaporation in vacuo on Rotary Evaporators is formed thin film; The phosphate buffer and the ferriferrous oxide nano magnetic particle that add pH=7.4, behind ultrasonic 60 minutes of probe, the non-encapsulated magnetic material of the supernatant and the bottle end is abandoned in centrifugalize, gets middle level brown aqueous suspension, promptly makes the magnetic lipid liquid solution;
C, configuration concentration are the 20mg/ml chitosan-acetic acid solution, and magnetic stirred 12 hours, and the magnetic lipid liquid solution slowly is added drop-wise in the chitosan-acetic acid solution, continue to stir 2 hours, promptly make chitosan-modified magnetic liposome.
Described surfactant is cetyl trimethyl ammonium bromide or sodium lauryl sulphate or Triton X-100.
Described cosurfactant is cholesterol or n-octyl alcohol or glycerol.
Described chitosan is that deacetylation is the chitosan of 50-95%.
Preparation method of the present invention is simple, and is workable, can further satisfy and produce and demands of applications; The contrast agent of the present invention's preparation has good physical and chemical stability; Adopt chitosan that intestinal mucosa is had good specificity among the present invention, help improving the effective rate of utilization of contrast agent.
The chitosan-modified magnetic liposome of the present invention's preparation has good application aspect intestinal tract contrast agent, and preparation technology is simple, and production cost is low, and the contrast agent good stability of gained can further satisfy and produce and demands of applications.
The specific embodiment
Below by specific embodiment technical scheme of the present invention is further described.Following embodiment further specifies of the present invention, and does not limit the scope of the invention.
Embodiment 1
1, the preparation of ferriferrous oxide nano magnetic particle
In 10 ml waters, add 02 gram ferric chloride respectively, 0.1 gram ferrous chloride and 0.05 gram Triton X-100, being configured to concentration is the solution of 20mg/ml ferric chloride, 10mg/ml ferrous chloride and 5mg/ml Triton X-100.With this solution under 50 ℃ and inert atmosphere, vigorous stirring is after 30 minutes, regulating pH value with the 3M sodium hydroxide solution is 8.Keep temperature, continue to stir after 30 minutes, deionized water, washing with alcohol are used in centrifugalize respectively, promptly make the ferriferrous oxide nano magnetic particle.
2, the preparation of magnetic liposome
Take by weighing 0.1g phospholipid and 0.1g cholesterol respectively, be dissolved in fully in the mixed phase of 10 milliliters of chloroforms and distilled water, the volume ratio of chloroform and water is 1: 1, and being configured to concentration is the mixed solution of the chloroform/distilled water of 10mg/ml phospholipid and 10mg/ml cholesterol.This solution rotary evaporation in vacuo on Rotary Evaporators is formed thin film.Add 100 milliliters of pH=7.4 phosphate buffers and 10 milligrams of ferriferrous oxide nano magnetic particles that make, behind ultrasonic 60 minutes of probe, the non-encapsulated magnetic material of the supernatant and the bottle end is abandoned in centrifugalize, get middle level brown aqueous suspension, promptly make the magnetic lipid liquid solution.
3, the preparation of chitosan-modified magnetic liposome
Taking by weighing 0.1 gram deacetylation is 50% chitosan, is dissolved in 5 milliliter 1% the acetum, is configured to the chitosan-acetic acid solution that concentration is 20mg/ml, and magnetic stirred 12 hours.The magnetic lipid liquid solution that makes slowly is added drop-wise in the chitosan-acetic acid solution, and the dropping time is 10 minutes, continues to stir 2 hours, promptly makes chitosan-modified magnetic liposome.
Making chitosan-modified magnetic lipid body preparation is white opacity liquid, and the dynamic laser light scattering method detects vesicle mean diameter: 240.5nm.
Embodiment 2
1, the preparation of ferriferrous oxide nano magnetic particle
In 10 ml waters, add 0.1 gram ferric chloride respectively, 0.05 gram ferrous chloride and 0.05 gram cetyl trimethyl ammonium bromide, being configured to concentration is the solution of 10mg/ml ferric chloride, 5mg/ml ferrous chloride and 5mg/ml cetyl trimethyl ammonium bromide.With this solution under 80 ℃ and inert atmosphere, vigorous stirring is after 30 minutes, regulating pH value with the 3M sodium hydroxide solution is 9.Keep temperature, continue to stir after 30 minutes, deionized water, washing with alcohol are used in centrifugalize respectively, promptly make the ferriferrous oxide nano magnetic particle.
2, the preparation of magnetic liposome
Take by weighing 0.1 gram phospholipid and 0.1 gram glycerol respectively, be dissolved in fully in the mixed phase of 10 milliliters of chloroforms and distilled water, the volume ratio of chloroform and water is 3: 1, being configured to concentration is the chloroform of 10mg/ml phospholipid and 10mg/ml glycerol and the mixed solution of distilled water, and this solution rotary evaporation in vacuo on Rotary Evaporators is formed thin film.Add 100 milliliters of pH=7.4 phosphate buffers and 50 milligrams of ferriferrous oxide nano magnetic particles that make, behind ultrasonic 60 minutes of probe, the non-encapsulated magnetic material of the supernatant and the bottle end is abandoned in centrifugalize, get middle level brown aqueous suspension, promptly make the magnetic lipid liquid solution.
3, the preparation of chitosan-modified magnetic liposome
Taking by weighing 0.1 gram deacetylation is 70% chitosan, is dissolved in 5 milliliter 1% the acetum, is configured to the chitosan-acetic acid solution that concentration is 20mg/ml.Magnetic stirred 12 hours, and the magnetic lipid liquid solution that makes slowly is added drop-wise in the chitosan-acetic acid solution, and the dropping time is 10 minutes, continued to stir 2 hours, promptly made chitosan-modified magnetic liposome.
Making chitosan-modified magnetic lipid body preparation is white opacity liquid, and the dynamic laser light scattering method detects vesicle mean diameter: 186.4nm.
Embodiment 3
1, the preparation of ferriferrous oxide nano magnetic particle
In 10 ml waters, add 0.1 gram ferric chloride respectively, 0.1 gram ferrous chloride and 0.1 gram sodium lauryl sulphate, being configured to concentration is 10mg/ml ferric chloride, 10mg/ml ferrous chloride and 10mg/ml sodium lauryl sulphate.With this solution under 80 ℃ and inert atmosphere, vigorous stirring is after 30 minutes, regulating pH value with the 3M sodium hydroxide solution is 11.Keep temperature, continue to stir after 30 minutes, deionized water, washing with alcohol are used in centrifugalize respectively, promptly make the ferriferrous oxide nano magnetic particle.
2, the preparation of magnetic liposome
Take by weighing 02 gram phospholipid and 0.1 gram n-octyl alcohol respectively, be dissolved in fully in the mixed phase of 10 milliliters of chloroforms and distilled water, the volume ratio of chloroform and water is 1: 3, and being configured to concentration is the chloroform of 20mg/ml phospholipid and 10mg/ml n-octyl alcohol and the mixed solution of distilled water.This solution rotary evaporation in vacuo on Rotary Evaporators is formed thin film.Add the ferriferrous oxide nano magnetic particle that 100ml pH=7.4 phosphate buffer and 10mg make, behind ultrasonic 60 minutes of probe, the non-encapsulated magnetic material of the supernatant and the bottle end is abandoned in centrifugalize, get middle level brown aqueous suspension, promptly make the magnetic lipid liquid solution.
3, the preparation of chitosan-modified magnetic liposome
Taking by weighing 0.1 gram deacetylation is 95% chitosan, is dissolved in 5ml, in 1% the acetum, is configured to the chitosan-acetic acid solution that concentration is 20mg/ml, and magnetic stirred 12 hours.The magnetic lipid liquid solution slowly is added drop-wise in the chitosan-acetic acid solution, and the dropping time is 10 minutes, continues to stir 2 hours, promptly makes chitosan-modified magnetic liposome.
Making chitosan-modified magnetic lipid body preparation is white opacity liquid, and the dynamic laser light scattering method detects vesicle mean diameter: 365.4nm.
Claims (4)
1. the preparation method of chitosan-modified magnetic liposome is characterized in that:
A, configuration concentration are the solution of 10-20mg/ml ferric chloride, 5-10mg/ml ferrous chloride and 5-10mg/ml surfactant, with this solution under 50-80 ℃ and inert atmosphere, vigorous stirring is after 30 minutes, regulating pH value with sodium hydroxide solution is 8-11; Keep temperature, continue to stir after 30 minutes, deionized water, washing with alcohol are used in centrifugalize respectively, promptly make the ferriferrous oxide nano magnetic particle;
B, configuration concentration are that the volume ratio of chloroform and water is 3: 1-1: 3 in the mixed phase of the chloroform of 10-20mg/ml phospholipid and 10mg/ml cosurfactant and distilled water; This solution rotary evaporation in vacuo on Rotary Evaporators is formed thin film; Add the phosphate buffer of pH=7.4 and the ferriferrous oxide nano magnetic particle that makes, behind ultrasonic 60 minutes of probe, the non-encapsulated magnetic material of the supernatant and the bottle end is abandoned in centrifugalize, gets middle level brown aqueous suspension, promptly makes the magnetic lipid liquid solution;
C, configuration concentration are the 20mg/ml chitosan-acetic acid solution, and magnetic stirred 12 hours, and the magnetic lipid liquid solution that makes slowly is added drop-wise in the chitosan-acetic acid solution, continue to stir 2 hours, promptly make chitosan-modified magnetic liposome.
2. the preparation method of chitosan-modified magnetic liposome according to claim 1 is characterized in that described surfactant is cetyl trimethyl ammonium bromide or sodium lauryl sulphate or Triton X-100.
3. the preparation method of chitosan-modified magnetic liposome according to claim 1 is characterized in that, described cosurfactant is cholesterol or n-octyl alcohol or glycerol.
4. the preparation method of chitosan-modified magnetic liposome according to claim 1 is characterized in that, described chitosan is that deacetylation is the chitosan of 50-95%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105714211A CN102000351A (en) | 2010-12-02 | 2010-12-02 | Method for preparing chitosan-modified magnetic liposomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105714211A CN102000351A (en) | 2010-12-02 | 2010-12-02 | Method for preparing chitosan-modified magnetic liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102000351A true CN102000351A (en) | 2011-04-06 |
Family
ID=43808219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105714211A Pending CN102000351A (en) | 2010-12-02 | 2010-12-02 | Method for preparing chitosan-modified magnetic liposomes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102000351A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102793672A (en) * | 2012-08-21 | 2012-11-28 | 南京医科大学 | Chitosan-modified methazolamide solid lipid nanoparticles and preparation method thereof |
| CN106387625A (en) * | 2016-08-31 | 2017-02-15 | 秦皇岛长胜营养健康科技有限公司 | Chitosan modified asparagus lipidosome and preparation method thereof |
| CN106692993A (en) * | 2017-01-04 | 2017-05-24 | 中国科学院自动化研究所 | Specific targeted magnetic resonance-optical dual-mode imaging probe and preparation method thereof |
| CN107903341A (en) * | 2017-07-27 | 2018-04-13 | 大连民族大学 | The application of double fat chain substituent phosphatidyl-ethanolamine chitosans |
| CN110571005A (en) * | 2019-09-27 | 2019-12-13 | 广西科技大学 | Immobilized metal ion-magnetic liposome and preparation method and application thereof |
| CN115121225A (en) * | 2022-06-27 | 2022-09-30 | 中国药科大学 | Magnetic liposome for enriching THC, preparation method and application thereof |
-
2010
- 2010-12-02 CN CN2010105714211A patent/CN102000351A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102793672A (en) * | 2012-08-21 | 2012-11-28 | 南京医科大学 | Chitosan-modified methazolamide solid lipid nanoparticles and preparation method thereof |
| CN106387625A (en) * | 2016-08-31 | 2017-02-15 | 秦皇岛长胜营养健康科技有限公司 | Chitosan modified asparagus lipidosome and preparation method thereof |
| CN106692993A (en) * | 2017-01-04 | 2017-05-24 | 中国科学院自动化研究所 | Specific targeted magnetic resonance-optical dual-mode imaging probe and preparation method thereof |
| CN106692993B (en) * | 2017-01-04 | 2019-12-31 | 中国科学院自动化研究所 | Specific targeted magnetic resonance-optical dual-mode imaging probe and preparation method thereof |
| CN107903341A (en) * | 2017-07-27 | 2018-04-13 | 大连民族大学 | The application of double fat chain substituent phosphatidyl-ethanolamine chitosans |
| CN110571005A (en) * | 2019-09-27 | 2019-12-13 | 广西科技大学 | Immobilized metal ion-magnetic liposome and preparation method and application thereof |
| CN110571005B (en) * | 2019-09-27 | 2021-01-01 | 广西科技大学 | Immobilized metal ion-magnetic liposome and preparation method and application thereof |
| CN115121225A (en) * | 2022-06-27 | 2022-09-30 | 中国药科大学 | Magnetic liposome for enriching THC, preparation method and application thereof |
| CN115121225B (en) * | 2022-06-27 | 2024-04-19 | 中国药科大学 | Magnetic liposome for enriching THC, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abdelhamid | Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review | |
| Han et al. | Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice | |
| Barui et al. | Biomedical applications of zinc oxide nanoparticles | |
| US20210212948A1 (en) | Nanovesicles derived from cell membrane, and use thereof | |
| CN102000351A (en) | Method for preparing chitosan-modified magnetic liposomes | |
| Li et al. | Intelligent nanogels with self-adaptive responsiveness for improved tumor drug delivery and augmented chemotherapy | |
| CN104043137B (en) | Intestinal-specific magnetic resonance contrast agent based on mesoporous silicon oxide and preparation method thereof | |
| Meng et al. | Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy | |
| Radhakrishnan et al. | Dual enzyme responsive and targeted nanocapsules for intracellular delivery of anticancer agents | |
| Cheng et al. | Tumor-microenvironment-responsive size-shrinkable drug-delivery nanosystems for deepened penetration into tumors | |
| CN107308457A (en) | A kind of deep layer degraded with tumor microenvironment response penetrates nanoscale medicine delivery system | |
| CN104910252A (en) | PH response type lipid based on dendrimers as well as preparation method and application of pH response type lipid | |
| CN106798726B (en) | A kind of targeting carries medicine silica nodule and preparation and application | |
| WO2023174173A1 (en) | Liposome drug carrier combined with blood cell membrane, and preparation method therefor and application thereof | |
| Wang et al. | Mitochondria-targeting folic acid-modified nanoplatform based on mesoporous carbon and a bioactive peptide for improved colorectal cancer treatment | |
| Fu et al. | Implantable fibrous scaffold with hierarchical microstructure for the ‘on-site’synergistic cancer therapy | |
| CN104511017A (en) | Drug composition reducing in-vivo and in-vitro toxicity of nano drug delivery material and preparation method thereof | |
| CN108904817B (en) | PEG/g-C3N4Quantum dot composite fluorescent nano-microsphere and application thereof | |
| Yang et al. | Biodegradable doxorubicin-loaded ferric phosphate nanosheets for specific tumor elimination through autophagy inhibition-enhanced apoptosis/ferroptosis pathway | |
| CN109106695A (en) | A kind of preparation method of the segmented intestine targeted sustained-release micro-spheres of brufen | |
| CN101850118B (en) | Preparation method and application in preparation of photodynamic therapy medicines of fat-soluble photosensitizer loaded on inorganic salt carrier | |
| CN109662956B (en) | Application of oleanolic acid grafted chitosan drug-loaded nanoparticles | |
| CN104045823A (en) | Glycyrrhetinic acid derivative, and preparation method and application thereof | |
| WO2020228206A1 (en) | Method for preparing cisplatin nano-drug for treatment of ovarian cancer | |
| Shu et al. | New generation of β-cyclodextrin-chitosan nanoparticles encapsulated quantum dots loaded with anticancer drug for tumor-target drug delivery and imaging of cancer cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110406 |